SCHEMBL1027755

SCHEMBL1027755

COC(=O)c1ccc2c(c1)CCN(C(=O)O)C2

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.56
HDAC8 Q9BY41 2/20 0.56
ESR2 Q92731 2/20 0.50
ESR1 P03372 1/20 0.50
ACACB O00763 1/20 0.49
MAPK1 P28482 1/20 0.48
NAMPT P43490 3/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TMPRSS2 O15393 1/20 0.46
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277266 0.94 HDAC6 (0.51) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL30810841 0.94 HDAC6 (0.51) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL2727794 0.92 HDAC6 (0.58) HDAC6HDAC8ACACBNAMPT
SCHEMBL31276014 0.89 HDAC6 (0.56) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL12682930 0.89 HDAC6 (0.56) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL1027717 0.88 NAMPT (0.54) HDAC6HDAC8ACACBNAMPTCA1
SCHEMBL1263724 0.85 HDAC6 (0.53) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL8283285 0.85 ESR2 (0.70) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL20178664 0.84 HDAC6 (0.51) HDAC6HDAC8ESR2ESR1ACACB
SCHEMBL10120405 0.84 HDAC6 (0.52) HDAC6HDAC8ESR2ESR1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584263-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF Chong Kun Dang Pharmaceutical Corp. (KR) 2025-07-16 EP disclosed
WO-2024054071-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2024-03-14 WO disclosed
US-8575193-B2 N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds 4SC AG (DE) 2013-11-05 US disclosed
US-20110201643-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2011-08-18 US disclosed
US-20110112103-A1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-12 US disclosed
EP-2274283-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2011-01-19 EP disclosed
WO-2009112550-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS 4SC AG (DE) 2009-09-17 WO disclosed
EP-2100879-A1 Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds 4SC AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112103-A1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND EPOR, CBR1, CBR3 HDAC6 1531/4885HDAC8 1926/4885ESR2 93/4885
US-20110201643-A1 NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS HDAC1, HDAC3, HDAC4 HDAC6 7/4885HDAC8 10/4885ESR2 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.